文献速递心脑血管急症

无保护左主干狭窄经皮冠状动脉介入治疗与冠状动脉旁路移植术比较:随机、开放标签、非劣效性NOBLE试验10年最终结果

Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial.
PubMed 文献 · Lancet · 2026-01-01
一句话结论NOBLE试验10年随访显示,对无保护左主干狭窄且无额外复杂病变、两种治疗均适用的患者,PCI与CABG全因死亡率无显著差异。

NOBLE试验在丹麦、爱沙尼亚、芬兰、德国、拉脱维亚、立陶宛、挪威、瑞典和英国36家医院纳入无保护左主干狭窄患者,由多学科心脏团队按临床标准(慢性或急性冠脉综合征且预期寿命>1年)和造影标准(左主干直径狭窄≥50%或左主干开口、中段或分叉处血流储备分数≤0.80)判定资格,排除24小时内ST段抬高型心肌梗死或被认为CABG或PCI风险过高的患者。1201例患者随机1:1接受PCI(n=598)或CABG(n=603),每组592例纳入意向性治疗人群。10年全因死亡率PCI组136例(23%) vs CABG组145例(25%),HR 0.93(95%CI 0.74-1.18),P=0.56,无显著差异;按SYNTAX评分也未发现全因死亡率显著差异。作者认为,对无保护左主干冠状动脉疾病且无额外复杂病变、两种治疗均适用的患者,PCI与CABG同样安全,结果有助于心脏团队制定个体化以患者为中心的策略。

要点

  • 10年全因死亡率:PCI组136/592(23%) vs CABG组145/592(25%),HR 0.93(95%CI 0.74-1.18),P=0.56,无显著差异。
  • 适用人群为无保护左主干狭窄且无额外复杂病变、经心脏团队评估两种治疗均适用的患者。
  • 按SYNTAX评分未发现全因死亡率显著差异,提示PCI在符合条件患者中与CABG同样安全。
  • 随机分组按中心、性别、左主干远端分叉病变和糖尿病分层。
  • 研究纳入急性冠脉综合征患者,但排除24小时内ST段抬高型心肌梗死。

适用人群与场景

  • 无保护左主干冠状动脉狭窄患者,由多学科心脏团队判定资格。
  • 临床标准:慢性或急性冠脉综合征且预期寿命>1年。
  • 造影标准:左主干直径狭窄≥50%或左主干开口、中段或分叉处血流储备分数≤0.80。
  • 排除24小时内ST段抬高型心肌梗死患者。
  • 排除被认为CABG或PCI风险过高的患者。

诊断标准与关键阈值

  • 造影确认显著左主干病变:左主干直径狭窄≥50%或左主干开口、中段或分叉处血流储备分数≤0.80。
  • 临床标准:慢性或急性冠脉综合征且预期寿命>1年。
  • 资格由多学科心脏团队判定。

红旗征与不能漏的情况

  • 24小时内ST段抬高型心肌梗死患者被排除。
  • 被认为CABG或PCI风险过高的患者被排除。

研究设计与关键结果

  • 研究类型:前瞻性、随机、开放标签、非劣效性试验,36家医院参与,纳入1201例患者随机1:1至PCI(n=598)或CABG(n=603)。
  • 意向性治疗人群每组592例;平均年龄PCI组66.2岁(SD 9.9),CABG组66.2岁(SD 9.4);女性256/1184(22%),男性928/1184(78%)。
  • 主要终点10年全因死亡率:PCI组136/592(23%) vs CABG组145/592(25%),HR 0.93(95%CI 0.74-1.18),P=0.56,无显著差异。
  • 按SYNTAX评分未发现全因死亡率显著差异。

证据类型、等级与局限

  • 证据类型:随机、开放标签、非劣效性试验(NOBLE试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对无保护左主干冠状动脉疾病且无额外复杂病变、两种治疗均适用的患者,PCI与CABG同样安全。
  • 作者认为,这些结果有助于心脏团队制定个体化以患者为中心的策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Coronary artery bypass grafting (CABG) is recommended over percutaneous coronary intervention (PCI) for patients with significant unprotected left main coronary artery disease. We aim to provide long-term outcome data comparing PCI with newer generation drug-eluting stents and CABG, which are scarce.

METHODS: This previously published, prospective, randomised, open-label, non-inferiority trial enrolled patients with unprotected left main coronary artery stenosis at 36 hospitals in Denmark, Estonia, Finland, Germany, Latvia, Lithuania, Norway, Sweden, and the UK. Eligibility was determined by a multidisciplinary heart team and defined by clinical criteria (chronic or acute coronary syndrome and a life expectancy of >1 year) and angiographic criteria (left main coronary artery diameter stenosis ≥50% or fractional flow reserve ≤0·80 in the left main ostium, mid-shaft, or bifurcation). Patients with ST elevation myocardial infarction within 24 h or considered at too high risk for CABG or PCI were excluded. Patients with angiographically confirmed significant left main coronary artery disease were randomly assigned (1:1) to PCI or CABG using an online system and stratified by site, sex, distal left main coronary artery bifurcation lesions, and diabetes. The primary outcome was the difference in 10-year all-cause mortality in the intention-to-treat (ITT) population, which was analysed using Kaplan-Meier estimates and unadjusted Cox regression. Patients were censored at the date of death, emigration, withdrawal, or loss to follow-up. Variation in all-cause mortality was assessed in prespecified subgroups. The trial is registered with ClinicalTrials.gov, NCT01496651 (active, not recruiting).

FINDINGS: From Dec 9, 2008, to Jan 21, 2015, 1201 patients were randomly assigned to PCI (n=598) or CABG (n=603). 17 patients were lost to follow-up before 1 year. 592 patients in each group were included in the ITT population. Mean age was 66·2 years (SD 9·9) in the PCI group and 66·2 years (9·4) in the CABG group. 256 (22%) of 1184 participants were female and 928 (78%) were male. There was no difference in all-cause mortality at 10 years (136 [23%] of 592 in the PCI group and 145 [25%] of 592 in the CABG group; hazard ratio 0·93 [95% CI 0·74-1·18]; p=0·56). No significant difference in all-cause mortality with SYNTAX score was identified.

INTERPRETATION: There was no significant difference in all-cause mortality at 10 years between PCI and CABG for patients with unprotected left main coronary artery disease and no additional complex lesions, indicating that PCI is equally as safe as CABG in patients eligible for both treatments. These results will aid heart teams in developing an individualised patient-centred strategy.

FUNDING: Biosensors and Aarhus University Hospital.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Holck EN, Holm NR, Hildick-Smith D, et al. Percutaneous coronary intervention versus coronary artery bypass grafting for unprotected left main stenosis: 10-year final results from the randomised, open-label, non-inferiority NOBLE trial. Lancet. 2026. PMID: 41936368. doi:10.1016/S0140-6736(26)00205-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。